Clinical trials: Benign Hyperplasia of Prostate
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS
Benign prostatic hyperplasia (BPH) and its related symptoms are a common condition that affects nearly half of men over age 50 and 90% of men over 80.
- Trial name
- NCT01589263
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- VA Office of Research and Development
Prostatic Hyperplasia
Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
This retrospective study aims to quantify the relationship between 5-alpha-reductase inhibitor (5ARI) adherence / length of therapy and the likelihood of acute urinary retention (AUR) or prostate surgery in patients with benign…
- Trial name
- NCT01334723
- Testing
- Adherent with 5-alpha-reductase inhibitor (5ARI) therapy, Non-adherent to 5ARI therapy
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
This is a investigator-initiated evaluation of the safety and efficacy of treating benign prostatic hyperplasia (BPH) by prostatic artery embolization.
- Trial name
- NCT02930889
- Testing
- Prostate Artery Embolization
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Minnesota
Benign Prostatic Hyperplasia, Enlarged Prostate
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate…
- Trial name
- NCT01139762
- Testing
- Tadalafil, Finasteride
- Where
- 65 sites in United States, Argentina and 11 more
- Volunteers
- 696 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Investigator-initiated study to evaluate the safety and efficacy of prostate artery embolization for the treatment lower urinary tract symptoms in patients with benign prostatic hyperplasia
- Trial name
- NCT03055624
- Testing
- Embosphere microparticles for prostate artery embolization
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Diego
Prostatic Hyperplasia
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related…
- Trial name
- NCT01332487
- Testing
- 5ARI + AB
- Volunteers
- 4,068 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia
The purpose of this study is to compare the UroLift System Treatment to Transurethral Resection of the Prostate (TURP) in improving a patient's overall quality of life, while evaluating healthcare expenditures associated with…
- Trial name
- BPH-6 (NCT01533038)
- Testing
- UroLift System, Transurethral Resection of the Prostate
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- NeoTract, Inc.
Benign Prostatic Hyperplasia
Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men
The primary purpose of this clinical trial is to evaluate the change in the International Prostate Symptom Score (IPSS) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg…
- Trial name
- NCT00540124
- Testing
- Tadalafil, Tamsulosin
- Where
- 5 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects
This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
- Trial name
- NCT00368979
- Testing
- Dutasteride
- Where
- 26 sites in Japan
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia
The purpose of this study is to assess the safety and effectiveness of S-equol in men with benign prostatic hyperplasia.
- Trial name
- NCT00962390
- Testing
- S-equol
- Where
- 15 sites in United States, India
- Volunteers
- 116 people
- Sponsor
- Ausio Pharmaceuticals, LLC
Benign Prostatic Hypertrophy
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00663858
- Testing
- Cetrorelix 78+78
- Where
- 54 sites in Belarus, Bulgaria and 8 more
- Volunteers
- 420 people
- Sponsor
- AEterna Zentaris
Benign Prostatic Hyperplasia (BPH)
Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
This is an investigator-initiated study of safety, efficacy and tolerability of dutasteride given for 18 months, including a 1-year double-blind randomized co-administration with either tolterodine ER or placebo in men suffering…
- Trial name
- LUTS (NCT00939120)
- Testing
- Tolterodine ER 4mg, Pre-randomization Dutasteride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Siami, Paul F., M.D.
Benign Prostatic Hyperplasia
Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design, multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12 weeks in Asian men with signs and…
- Trial name
- NCT00861757
- Testing
- Tadalafil, Tamsulosin
- Where
- 6 sites in Japan, Taiwan
- Volunteers
- 612 people
- Sponsor
- Eli Lilly and Company
Hypogonadism, Benign Prostatic Hyperplasia
TRADE-Testosterone Replacement and Dutasteride Effectiveness
The purpose of this research study is to determine whether the combination of the male hormone testosterone [T] in gel form and the oral drug dutasteride [D], used to shrink large prostate glands can safely reduce the size of the…
- Trial name
- TRADE (NCT00194675)
- Testing
- Dutasteride, Testosterone gel
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Washington
Benign Prostatic Hyperplasia
Urodynamic Feasibility Study Utilizing the UroLift® System
UDS evaluates the impact of Prostatic Urethral Lift (PUL) as measured by pressure flow, urodynamic testing (UDS) and an optional UroCuff Testing, an alternative urodynamic test.
- Trial name
- UDS (NCT04271020)
- Testing
- UroLift
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- NeoTract, Inc.
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Benign Prostatic Hypertrophy
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00449150
- Testing
- Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg
- Where
- 68 sites in United States, Bulgaria and 2 more
- Volunteers
- 667 people
- Sponsor
- AEterna Zentaris
Benign Prostatic Hyperplasia
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224120
- Testing
- Silodosin
- Where
- 42 sites in United States
- Volunteers
- 462 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia, Adenoma, Prostatic
Rezum FIM Optimization Study
Evaluate the effect of the NxThera BPH Rezum System on prostate tissue in subjects suffering from LUTS symptoms secondary to benign prostatic hyperplasia (BPH).
- Conditions
- Benign Prostatic Hyperplasia, Adenoma, Prostatic, Prostatic Adenoma, Prostatic Hyperplasia, Benign
- Trial name
- Rezum FIM (NCT02940392)
- Testing
- Rezum System
- Where
- Dominican Republic
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation